Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HRAS | P01112 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27725217 | 0.86 | TSHR (0.45) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL7214230 | 0.85 | NPC1 (0.50) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL3971071 | 0.83 | NPC1 (0.42) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL1160560 | 0.76 | NPC1 (0.55) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL27453500 | 0.74 | NPC1 (0.46) | NPC1RAB9ACA1CA2CA9 | |
| SCHEMBL4282703 | 0.73 | CA1 (0.46) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL4282571 | 0.73 | CA1 (0.46) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL27536452 | 0.73 | CA1 (0.46) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL4422666 | 0.73 | NPC1 (0.45) | NPC1RAB9ACA1ALDH1A1CA12 | |
| SCHEMBL28460302 | 0.72 | TACR1 (0.43) | NPC1RAB9ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928475-B1 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES | RIBOSCIENCE LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-7608599-B2 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | NPC1 1467/4885RAB9A 165/4885TSHR 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.